• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Uncertain Results for Eszopiclone in PTSD

Uncertain Results for Eszopiclone in PTSD

March 26, 2021
Thomas Jordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Dowd SM et al, World J Psychiatry 2020;10(3):21–28


Study TYPE: Randomized, double-blind, placebo-controlled trial


The idea that good sleep promotes mental health has led researchers to test whether hypnotics have psychiatric benefits beyond their effects on sleep. Eszopiclone (Lunesta) fulfilled that promise in depression and generalized anxiety disorder, where it brought about more rapid and pronounced responses when added to SSRIs in two large, randomized, placebo-controlled trials. Although those trials enrolled patients with comorbid insomnia, their primary goal was to test whether eszo­piclone could improve core symptoms of depression and anxiety, which it did (Pollack M et al, Arch Gen Psychiatry 2008;65(5):551–562; Fava M et al, Biol Psychiatry 2006;59(11):1052–1060).


The current study was a small, randomized, double-blind, placebo-controlled trial that tested whether eszopiclone improved core symptoms of PTSD. After 12 weeks, the medication worked no better than placebo on measures of sleep or PTSD. In contrast, an earlier randomized crossover trial found significant effects for eszopiclone in both sleep and non-sleep symptoms of PTSD (Pollack MH et al, J Clin Psychiatry 2011;72(7):892–897), so which results should we believe?


The new study was hindered by a high dropout rate (36%). The Cochrane group considers dropout rates problematic when they rise above 20% in short-term trials and 30% in long-term ones. But the bigger lesson here is that the results of small trials—ie, fewer than 50 subjects—should never be taken at face value.


Randomization attempts to cancel out the effects of confounding variables, which is why most papers list a study’s baseline demographics before describing the results. If the randomization is successful, there should be a balanced distribution of women and men, older and younger subjects, mild and severe cases, etc, in both groups. However, no list can account for all of the confounding variables that might skew the results, and small samples make it more likely that the results were skewed by events that were unaccounted for, such as marital discord or changes in physical activity.


TCPR’s Take
While this study does little to clarify eszopiclone’s role in PTSD, it reminds us to give extra scrutiny to results from small (n < 50) trials, even when they are randomized and controlled.



podcastsTo learn more, listen to our 4/5/21 podcast, “Can Eszopiclone Augment Antidepressants?” Search for “Carlat” on your podcast store.


General Psychiatry
KEYWORDS ptsd
    Thomas Jordan, MD.

    Methylphenidate Max Dosing

    More from this author
    www.thecarlatreport.com
    Issue Date: March 26, 2021
    SUBSCRIBE NOW
    Table Of Contents
    In Brief: What Causes Affective Psychosis?
    Six Tips for Working With Older Adults
    Mood, Cognition, and Metabolic Health
    Antidepressants Harm Some With Bipolar Depression
    Uncertain Results for Eszopiclone in PTSD
    CME Post-Test - Metabolism and Mental Health, TCPR, April 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.